Danish CNS company Lundbeck announced six-month data from the 12-month, real-world INFUSE study, evaluating the effectiveness ...
Japanese drugmaker Kyowa Kirin late Friday announced the termination of the current rocatinlimab development and commercialization collaboration with US biotech major Amgen.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results